| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
6-(N-Boc)caproic acid NHS functions as a protein cross-linking agent and amine-reactive coupling reagent. Its primary targets are amine groups on proteins and peptides. The NHS ester moiety reacts with primary amines (such as the epsilon-amino group of lysine residues) to form stable amide bonds. This reaction allows the compound to cross-link proteins or to conjugate biomolecules. The Boc (tert-butoxycarbonyl) protecting group provides temporary protection of the amine functionality, which can be removed under acidic conditions for further derivatization. The compound's biochemical pathway involves the formation of covalent amide bonds with amine-containing molecules.
|
|---|---|
| ln Vitro |
In vitro studies of 6-(N-Boc)caproic acid NHS have focused on its role as a protein cross-linking agent and coupling reagent. The compound's reactivity with primary amines has been characterized in various in vitro systems. It is used in peptide synthesis to create complex biomolecules efficiently. The compound's purity of ≥98% supports its use in research applications. As an amine-reactive NHS ester, its reactivity and stability have been characterized in biochemical assays. These in vitro studies provide foundational data for understanding the compound's utility in bioconjugation and peptide synthesis applications.
|
| ln Vivo |
In vivo studies of 6-(N-Boc)caproic acid NHS are not applicable, as the compound is a research reagent used for in vitro bioconjugation rather than a therapeutic agent. The compound is used to modify proteins and peptides in vitro for research purposes. Its applications in peptide synthesis suggest it may be used in the production of peptides that are subsequently evaluated in vivo. However, the compound itself is not administered to living organisms. Its Boc protecting group is typically removed under acidic conditions before use, making the compound a temporary modification reagent. The compound is not intended for human therapeutic use.
|
| Enzyme Assay |
In vitro enzyme and receptor binding assays are not typically performed for 6-(N-Boc)caproic acid NHS, as the compound is a chemical coupling reagent rather than a biological agent. Its reactivity is assessed using analytical chemistry methods such as thin-layer chromatography (TLC) to confirm purity. The compound's ability to form amide bonds with amines is evaluated using standard bioconjugation protocols. High-performance liquid chromatography or mass spectrometry is used to confirm conjugation efficiency. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays are not applicable for 6-(N-Boc)caproic acid NHS, as the compound is a chemical reagent used for bioconjugation rather than a biological agent. The compound is used to modify proteins and peptides outside of cells. Its reactivity with primary amines is exploited in biochemical applications such as protein labeling and cross-linking. The compound is not intended for cell-based studies as a direct pharmacological agent. Cell-based assays may be used to evaluate the biological activity of peptides or proteins that have been modified using this compound, but the compound itself is not tested in cell-based systems.
|
| Animal Protocol |
In vivo animal experiments are not applicable for 6-(N-Boc)caproic acid NHS, as the compound is a research reagent used for in vitro bioconjugation rather than a therapeutic agent. The compound is not administered to animals for pharmacological evaluation. Its applications in peptide synthesis suggest it may be used in the production of peptides that are subsequently evaluated in animal models. However, the compound itself is not intended for in vivo use. All procedures involving the compound are conducted in laboratory settings for research purposes only.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 6-(N-Boc)caproic acid NHS are not applicable, as the compound is a research reagent used for in vitro bioconjugation rather than a therapeutic agent. It has a molecular weight of 328.36 and the molecular formula C15H24N2O6. The compound appears as a white powder and is stored as a powder at -20°C for up to 3 years. In solvent, it can be stored at -80°C for 6 months or at -20°C for 1 month. The compound is transported at room temperature in continental US. Its stability and reactivity are characterized in research applications.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 6-(N-Boc)caproic acid NHS has been evaluated in the context of its use as a research chemical. The compound is classified as a research chemical intended for laboratory use only. As an NHS ester, it is reactive and should be handled with care. Proper handling procedures including use of personal protective equipment are recommended. The compound is not approved for human therapeutic use. Long-term toxicity studies would be needed to fully establish its safety profile. The compound's reactivity with amines suggests it could potentially modify biological molecules if exposure occurs, emphasizing the need for proper handling and safety precautions.
|
| References | |
| Additional Infomation |
6-(N-Boc)caproic acid NHS (CAS# 51513-80-5) is also known as Boc-aminocaproic acid N-hydroxysuccinimide ester. It has the molecular formula C15H24N2O6 and a molecular weight of 328.36. The compound appears as a white powder with a purity of ≥98%. It serves as an amine-reactive coupling reagent and protein cross-linking agent for research applications. It is widely utilized in peptide synthesis. The compound is classified as a Biochemical Assay Reagent. It is stored as a powder at -20°C for up to 3 years. The compound is intended for research use only and is not for human therapeutic use.
|
| Molecular Formula |
C15H24N2O6
|
|---|---|
| Molecular Weight |
328.36
|
| Exact Mass |
328.163
|
| CAS # |
51513-80-5
|
| PubChem CID |
5074016
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2g/cm3
|
| Melting Point |
86-90ºC
|
| Index of Refraction |
1.507
|
| LogP |
2.007
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
23
|
| Complexity |
453
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)OC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O
|
| InChi Key |
TYJPSIQEEXOQLC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H24N2O6/c1-15(2,3)22-14(21)16-10-6-4-5-7-13(20)23-17-11(18)8-9-12(17)19/h4-10H2,1-3H3,(H,16,21)
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0454 mL | 15.2272 mL | 30.4544 mL | |
| 5 mM | 0.6091 mL | 3.0454 mL | 6.0909 mL | |
| 10 mM | 0.3045 mL | 1.5227 mL | 3.0454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
